公开(公告)号：US20200017581A1

公开(公告)日：2020-01-16

申请号：US16576323

申请日：2019-09-19

Applicant: AMGEN INC.

Inventor： Wei-Jian Pan ,  Wayne Tsuji

IPC: C07K16/24

Abstract: The invention relates to products and methods for treating Crohn's disease. The products relate to antibodies that inhibit native human IL-23 while sparing IL-12. One example describes a Phase 1, randomized, double-blind, placebo-controlled, ascending multiple dose study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of an anti-IL-23 antibody (AMG 139) in healthy subjects and subjects with mild to severe Crohn's disease.

公开(公告)号：US20200283517A1

公开(公告)日：2020-09-10

申请号：US16870038

申请日：2020-05-08

Applicant: AMGEN INC.

Inventor： Wei-Jian Pan ,  Wayne Tsuji

IPC: C07K16/24

Abstract: The invention relates to products and methods for treating Crohn's disease. The products relate to antibodies that inhibit native human IL-23 while sparing IL-12. One example describes a Phase 1, randomized, double-blind, placebo-controlled, ascending multiple dose study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of an anti-IL-23 antibody (AMG 139) in healthy subjects and subjects with mild to severe Crohn's disease.

公开(公告)号：US20140322209A1

公开(公告)日：2014-10-30

申请号：US14360087

申请日：2012-11-21

Applicant: AMGEN INC.

Inventor： Dominique Borie ,  Hailing Hsu ,  Wei-Jian Pan ,  Williams Rees ,  Barbara Sullivan

IPC: C07K16/28 ,  G01N33/569

CPC classification number: C07K16/2842 ,  A61K2039/505 ,  A61K2039/54 ,  A61K2039/545 ,  C07K16/2839 ,  C07K2317/90 ,  G01N33/56972 ,  G01N2333/70546 ,  G01N2800/065 ,  G01N2800/52

Abstract: There is provided a method of treating a subject afflicted with a condition that is associated with inappropriate trafficking of cells expressing alpha4beta7 to the gastrointestinal tract, comprising administering to the subject an alpha4beta7 heterodimer specific antibody in an amount and at an interval sufficient to ameliorate the condition.

Abstract translation: 提供了一种治疗受到与向胃肠道表达α4β7的细胞不适当运送相关的病症的受试者的方法，包括以足以改善病症的量和间隔向受试者施用α4β7异二聚体特异性抗体 。

公开(公告)号：US20180327490A1

公开(公告)日：2018-11-15

申请号：US15819159

申请日：2017-11-21

Applicant: AMGEN INC.

Inventor： Wei-Jian Pan ,  Wayne Tsuji

IPC: C07K16/24 ,  A61K39/00

CPC classification number: C07K16/244 ,  A61K2039/505 ,  A61K2039/54 ,  A61K2039/545 ,  C07K2317/21 ,  C07K2317/76 ,  C07K2317/90 ,  C07K2317/94

Abstract: The invention relates to products and methods for treating Crohn's disease. The products relate to antibodies that inhibit native human IL-23 while sparing IL-12. One example describes a Phase 1, randomized, double-blind, placebo-controlled, ascending multiple dose study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of an anti-IL-23 antibody (AMG 139) in healthy subjects and subjects with mild to severe Crohn's disease.

公开(公告)号：US09914779B2

公开(公告)日：2018-03-13

申请号：US14360087

申请日：2012-11-21

Applicant: AMGEN INC.

Inventor： Dominique Christian Borie ,  Hailing Hsu ,  Wei-Jian Pan ,  William Rees ,  Barbara Anne Sullivan

IPC: A61K39/395 ,  C07K16/18 ,  C07K16/28 ,  G01N33/569 ,  A61K39/00

CPC classification number: C07K16/2842 ,  A61K2039/505 ,  A61K2039/54 ,  A61K2039/545 ,  C07K16/2839 ,  C07K2317/90 ,  G01N33/56972 ,  G01N2333/70546 ,  G01N2800/065 ,  G01N2800/52

Abstract: There is provided a method of treating a subject afflicted with a condition that is associated with inappropriate trafficking of cells expressing alpha4beta7 to the gastrointestinal tract, comprising administering to the subject an alpha4beta7 heterodimer specific antibody in an amount and at an interval sufficient to ameliorate the condition.

公开(公告)号：US20220135668A1

公开(公告)日：2022-05-05

申请号：US17574980

申请日：2022-01-13

Applicant: AMGEN INC.

Inventor： John P. Gibbs, II ,  Wayne Tsuji ,  Wei-Jian Pan

IPC: C07K16/24 ,  A61K39/00

Abstract: The invention relates to products and methods for treating psoriasis. The products relate to antibodies that inhibit native human IL-23 while sparing IL-12. One example describes a Phase 1, randomized, double-blind, placebo-controlled, ascending single dose study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of an anti-IL-23 antibody (AMG 139) in healthy subjects and subjects with moderate to severe psoriasis.

公开(公告)号：US20200277368A1

公开(公告)日：2020-09-03

申请号：US16598714

申请日：2019-10-10

Applicant: AMGEN INC.

Inventor： John P. Gibbs, II ,  Wayne Tsuji ,  Wei-Jian Pan

IPC: C07K16/24

Abstract: The invention relates to products and methods for treating psoriasis. The products relate to antibodies that inhibit native human IL-23 while sparing IL-12. One example describes a Phase 1, randomized, double-blind, placebo-controlled, ascending single dose study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of an anti-IL-23 antibody (AMG 139) in healthy subjects and subjects with moderate to severe psoriasis.

公开(公告)号：US20170218062A1

公开(公告)日：2017-08-03

申请号：US15487693

申请日：2017-04-14

Applicant: AMGEN INC.

Inventor： Wei-Jian Pan ,  Wayne Tsuji

IPC: C07K16/24

CPC classification number: C07K16/244 ,  A61K2039/505 ,  A61K2039/54 ,  A61K2039/545 ,  C07K2317/21 ,  C07K2317/76 ,  C07K2317/90 ,  C07K2317/94

Abstract: The invention relates to products and methods for treating Crohn's disease. The products relate to antibodies that inhibit native human IL-23 while sparing IL-12. One example describes a Phase 1, randomized, double-blind, placebo-controlled, ascending multiple dose study to evaluate the safety, tolerability, pharmacokinctics and pharmacodynamics of an anti-IL-23 antibody (AMG 139) in healthy subjects and subjects with mild to severe Crohn's disease.

公开(公告)号：US20160060337A1

公开(公告)日：2016-03-03

申请号：US14776222

申请日：2014-02-25

Applicant: AMGEN INC.

Inventor： John P. Gibbs ,  Wayne Tsuji ,  Wei-Jian Pan

IPC: C07K16/24

CPC classification number: C07K16/244 ,  A61K2039/505 ,  A61K2039/541 ,  A61K2039/545 ,  C07K2317/21 ,  C07K2317/76 ,  C07K2317/90

Abstract: The invention relates to products and methods for treating psoriasis. The products relate to antibodies that inhibit native human IL-23 while sparing IL-12. One example describes a Phase 1, randomized, double-blind, placebo-controlled, ascending single dose study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of an anti-IL-23 antibody (AMG 139) in healthy subjects and subjects with moderate to severe psoriasis.

Abstract translation: 本发明涉及治疗牛皮癣的产品和方法。 该产品涉及抑制天然人IL-23同时保护IL-12的抗体。 一个例子描述了1期随机，双盲，安慰剂对照，上升单剂量研究，以评估健康受试者和中度受试者的抗IL-23抗体（AMG 139）的安全性，耐受性，药代动力学和药效学 到严重的牛皮癣。

公开(公告)号：US20160031983A1

公开(公告)日：2016-02-04

申请号：US14776281

申请日：2014-02-25

Applicant: AMGEN INC.

Inventor： Wei-Jian Pan ,  Wayne Tsuji

IPC: C07K16/24

CPC classification number: C07K16/244 ,  A61K2039/505 ,  A61K2039/54 ,  A61K2039/545 ,  C07K2317/21 ,  C07K2317/76 ,  C07K2317/90 ,  C07K2317/94

Abstract: The invention relates to products and methods for treating Crohn's disease. The products relate to antibodies that inhibit native human IL-23 while sparing IL-12. One example describes a Phase 1, randomized, double-blind, placebo-controlled, ascending multiple dose study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of an anti-IL-23 antibody (AMG 139) in healthy subjects and subjects with mild to severe Crohn's disease.

Abstract translation: 本发明涉及治疗克罗恩病的产品和方法。 该产品涉及抑制天然人IL-23同时保护IL-12的抗体。 一个例子描述了1期随机，双盲，安慰剂对照，上升多剂量研究，以评估健康受试者和轻度受试者中抗IL-23抗体（AMG 139）的安全性，耐受性，药代动力学和药效学 到严重的克罗恩病。